Volunteers in north Wales are among 25,000 people taking part in a global trial to find a vaccine against the symptoms of the ...

Caroline Kennedy on Tuesday warned that her cousin Robert F. Kennedy Jr. is a “predator” ahead of his high-profile ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Nipah is one of the pathogens that Moderna has identified as the targets ... each will receive two doses of the investigational vaccine via injection in the shoulder muscle – 25 mcg, 50 mcg ...

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination ... dose of V940 via intramuscular (IM) injection or a matched placebo once ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in Phase 3 clinical trials, with the potential to be the first approved ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19 ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech that'll never recover its former glory -- which it built on the success of its ...